Everand Logo

Welcome to Everand!

  • STAT

    Welcome to the STAT China newsletter

    by Jonathan Chan Feb 18, 2020 4 minutes
    Source: FRED DUFOUR/AFP/Getty Images

    A version of this story first appeared in the weekly STAT China newsletter. To receive future editions, sign up here.

    Welcome to the first edition of the STAT China newsletter.

    My name is Jonathan Chan and I’m writing to you from the bustling city of Hong Kong. Every Tuesday morning — Tuesday night for those of you in my time zone — I will take you through some of the latest health care and biotech developments coming out of China.

    What will the newsletter look like? I’ll round up important stories from the past week, adding some analysis and reporting when I can. With ’s health care system going through reforms, I’ll also tell you about policy changes that could have implications

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
    Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
    STAT2 min readCrime & Violence
    STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
    A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related Books & Audiobooks